Randomised study of ezetimibe, start doses of original statins, and their combination in patients with coronary heart disease and hyperlipidemia Part 2. Therapy effects on the levels of C-reactive protein and proinflammatory cytokines
Aim. To assess the effects of original statins as monotherapy or in combination with ezetimibe on the levels of proinflammatory cytokines and high-sensitive C-reactive protein (hsCRP) in patients with coronary heart disease (CHD) and hyperlipidemia (HLP). Material and methods. The study included 60...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2011-12-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/1974 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850028308638466048 |
|---|---|
| author | A. V. Susekov M. Yu. Zubareva T. A. Rozhkova V. P. Masenko |
| author_facet | A. V. Susekov M. Yu. Zubareva T. A. Rozhkova V. P. Masenko |
| author_sort | A. V. Susekov |
| collection | DOAJ |
| description | Aim. To assess the effects of original statins as monotherapy or in combination with ezetimibe on the levels of proinflammatory cytokines and high-sensitive C-reactive protein (hsCRP) in patients with coronary heart disease (CHD) and hyperlipidemia (HLP). Material and methods. The study included 60 male and female patients with CHD, primary polygenic HLP, and the levels of low-density lipoprotein cholesterol (LDL-CH) of 2,9-4,9 mmol/l. Monotherapy with original statins or ezetimibe lasted for 6 months, while the combination therapy lasted for 3 months. In all randomised patients, the levels of hsCRP, interleukin 6 (IL-6), and monocyte chemotactic protein-1 (MCP-1) were measured at baseline, 12 and 24 weeks after the therapy started. Results. At baseline, median hsCRP levels in the groups of Ezetrol, Zocor, Liprimar, and Crestor monotherapy were 0,5-0,88 mg/l, with no significant dynamics after 3 months of the treatment. Baseline IL-6 levels across the monotherapy groups were 1,94-2,54 pg/ml; at 3 months, there was a non-significant reduction by 7-32 %. After 3 months of the therapy, the decrease in MCP-1 levels was not statistically significant (-1,3-7,7 %). The combined therapy did not result in a significant dynamics of hsCRP concentrations, with the exception of the group receiving Ezetrol and Liprimar. Although the combined therapy further reduced MCP-1 levels (by 30-78 pg/ml), these changes were not statistically significant. No significant difference was observed across statin and Ezetrol groups in terms of their effects on IL-6 and MCP-1 levels. Conclusion. The comparison of the three treatment schemes demonstrated similar, but not statistically significant reduction on the levels of hsCRP, IL-6, and MCP-1. No marked benefits were observed for either monotherapy or combination therapy over 12-24 weeks of the follow-up. |
| format | Article |
| id | doaj-art-1b1d2b863d934be39c043fd16699f8d5 |
| institution | DOAJ |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 2011-12-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-1b1d2b863d934be39c043fd16699f8d52025-08-20T02:59:52Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252011-12-01106818810.15829/1728-8800-2011-6-81-881686Randomised study of ezetimibe, start doses of original statins, and their combination in patients with coronary heart disease and hyperlipidemia Part 2. Therapy effects on the levels of C-reactive protein and proinflammatory cytokinesA. V. Susekov0M. Yu. Zubareva1T. A. Rozhkova2V. P. Masenko3A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical ComplexA.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical ComplexA.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical ComplexA.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical ComplexAim. To assess the effects of original statins as monotherapy or in combination with ezetimibe on the levels of proinflammatory cytokines and high-sensitive C-reactive protein (hsCRP) in patients with coronary heart disease (CHD) and hyperlipidemia (HLP). Material and methods. The study included 60 male and female patients with CHD, primary polygenic HLP, and the levels of low-density lipoprotein cholesterol (LDL-CH) of 2,9-4,9 mmol/l. Monotherapy with original statins or ezetimibe lasted for 6 months, while the combination therapy lasted for 3 months. In all randomised patients, the levels of hsCRP, interleukin 6 (IL-6), and monocyte chemotactic protein-1 (MCP-1) were measured at baseline, 12 and 24 weeks after the therapy started. Results. At baseline, median hsCRP levels in the groups of Ezetrol, Zocor, Liprimar, and Crestor monotherapy were 0,5-0,88 mg/l, with no significant dynamics after 3 months of the treatment. Baseline IL-6 levels across the monotherapy groups were 1,94-2,54 pg/ml; at 3 months, there was a non-significant reduction by 7-32 %. After 3 months of the therapy, the decrease in MCP-1 levels was not statistically significant (-1,3-7,7 %). The combined therapy did not result in a significant dynamics of hsCRP concentrations, with the exception of the group receiving Ezetrol and Liprimar. Although the combined therapy further reduced MCP-1 levels (by 30-78 pg/ml), these changes were not statistically significant. No significant difference was observed across statin and Ezetrol groups in terms of their effects on IL-6 and MCP-1 levels. Conclusion. The comparison of the three treatment schemes demonstrated similar, but not statistically significant reduction on the levels of hsCRP, IL-6, and MCP-1. No marked benefits were observed for either monotherapy or combination therapy over 12-24 weeks of the follow-up.https://cardiovascular.elpub.ru/jour/article/view/1974statinsezetimibecombination therapypro-inflammatory cytokinesc-reactive proteinhyperlipidemiacoronary heart disease |
| spellingShingle | A. V. Susekov M. Yu. Zubareva T. A. Rozhkova V. P. Masenko Randomised study of ezetimibe, start doses of original statins, and their combination in patients with coronary heart disease and hyperlipidemia Part 2. Therapy effects on the levels of C-reactive protein and proinflammatory cytokines Кардиоваскулярная терапия и профилактика statins ezetimibe combination therapy pro-inflammatory cytokines c-reactive protein hyperlipidemia coronary heart disease |
| title | Randomised study of ezetimibe, start doses of original statins, and their combination in patients with coronary heart disease and hyperlipidemia Part 2. Therapy effects on the levels of C-reactive protein and proinflammatory cytokines |
| title_full | Randomised study of ezetimibe, start doses of original statins, and their combination in patients with coronary heart disease and hyperlipidemia Part 2. Therapy effects on the levels of C-reactive protein and proinflammatory cytokines |
| title_fullStr | Randomised study of ezetimibe, start doses of original statins, and their combination in patients with coronary heart disease and hyperlipidemia Part 2. Therapy effects on the levels of C-reactive protein and proinflammatory cytokines |
| title_full_unstemmed | Randomised study of ezetimibe, start doses of original statins, and their combination in patients with coronary heart disease and hyperlipidemia Part 2. Therapy effects on the levels of C-reactive protein and proinflammatory cytokines |
| title_short | Randomised study of ezetimibe, start doses of original statins, and their combination in patients with coronary heart disease and hyperlipidemia Part 2. Therapy effects on the levels of C-reactive protein and proinflammatory cytokines |
| title_sort | randomised study of ezetimibe start doses of original statins and their combination in patients with coronary heart disease and hyperlipidemia part 2 therapy effects on the levels of c reactive protein and proinflammatory cytokines |
| topic | statins ezetimibe combination therapy pro-inflammatory cytokines c-reactive protein hyperlipidemia coronary heart disease |
| url | https://cardiovascular.elpub.ru/jour/article/view/1974 |
| work_keys_str_mv | AT avsusekov randomisedstudyofezetimibestartdosesoforiginalstatinsandtheircombinationinpatientswithcoronaryheartdiseaseandhyperlipidemiapart2therapyeffectsonthelevelsofcreactiveproteinandproinflammatorycytokines AT myuzubareva randomisedstudyofezetimibestartdosesoforiginalstatinsandtheircombinationinpatientswithcoronaryheartdiseaseandhyperlipidemiapart2therapyeffectsonthelevelsofcreactiveproteinandproinflammatorycytokines AT tarozhkova randomisedstudyofezetimibestartdosesoforiginalstatinsandtheircombinationinpatientswithcoronaryheartdiseaseandhyperlipidemiapart2therapyeffectsonthelevelsofcreactiveproteinandproinflammatorycytokines AT vpmasenko randomisedstudyofezetimibestartdosesoforiginalstatinsandtheircombinationinpatientswithcoronaryheartdiseaseandhyperlipidemiapart2therapyeffectsonthelevelsofcreactiveproteinandproinflammatorycytokines |